Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)

NCT03276936 is registered in ClinicalTrials.gov with Vyne Therapeutics Inc. as lead sponsor.

NCT NCT03276936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03276936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)
Lead sponsor
Vyne Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2017
Completion date
January 15, 2019
Enrollment
504 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

papulopustular rosacea